NCT07144592 The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
| NCT ID | NCT07144592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Muş Alparslan University |
| Condition | SCHIZOPHRENIA 1 (Disorder) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2025-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-01-01 with a primary completion date of 2025-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia. The study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30). The experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).
Eligibility Criteria
Inclusion Criteria: * Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria, Being between 18 and 65 years of age, Being literate and verbally communicative, Being clinically stable (not exhibiting symptoms of acute psychosis), Being registered with a Community Mental Health Center (CMHC) and receiving regular services, Being cognitively competent enough to participate in individual interviews during the research process, Being an individual currently receiving psychiatric treatment and taking medication, Agreeing to participate voluntarily in the study and signing a written informed consent form. Exclusion Criteria: * those who do not meet the inclusion criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07144592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying SCHIZOPHRENIA 1 (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07144592 currently recruiting?
Yes, NCT07144592 is actively recruiting participants. Contact the research team at fatih.sahin@alparslan.edu.tr for enrollment information.
Where is the NCT07144592 trial being conducted?
This trial is being conducted at Muş, Turkey (Türkiye).
Who is sponsoring the NCT07144592 clinical trial?
NCT07144592 is sponsored by Muş Alparslan University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.